Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”. The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve people’s quality of life by preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit’s series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.
ColonView lateral flow tests are intended for simple detection of fecal occult blood (FOB) in stool samples. The detection of blood is based on highly sensitive immunochemical detection of hemoglobin or hemoglobin/haptoglobin complex. The principal use of the Biohit ColonView Hb and Hb/Hp tests is to screen for lower gastrointestinal (GI) pathologies, such as colorectal cancers and large adenomas that bleed. The Biohit ColonVi…
